Business Wire

TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility

10.11.2025 17:10:00 CET | Business Wire | Press Release

Share

TOURISE, in collaboration with Oxford Economics, has released a new white paper titled “Growth Amid Uncertainty: Opportunities and Risks on the Road to 2 Billion Global Travellers,” unveiled during the inaugural TOURISE Summit. The publication presents key opportunities and risks that the industry will face in coming years as well as a framework to guide policymakers, destination leaders, and industry stakeholders in strengthening the tourism sector’s capacity to withstand global disruptions and foster long-term sustainability and resilience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110254503/en/

TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility

The white paper underscores the imperative of resilience as a foundational principle for tourism development in an era marked by geopolitical shifts, climate-related challenges, and evolving traveler expectations.

“Tourism has always been a force for connection and opportunity, but its true strength lies in its capacity to evolve and remain resilient. This white paper provides a clear direction for how the global tourism sector can navigate the years ahead, guiding us toward a future of sustainable growth and shared prosperity,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE.

“It demonstrates how data-driven planning and forward-looking policy can help destinations manage growth responsibly, withstand shocks, and continue creating jobs and opportunities. As we move toward two billion travelers by 2030, our focus must be on building a tourism ecosystem that is resilient, inclusive, and prepared for the challenges and possibilities of a changing world.”

Drawing on extensive data and economic modeling, the report identifies key trends shaping the future of travel and tourism. It highlights the growing importance of evidence-based decision-making and adaptive policy frameworks to ensure destinations remain competitive and inclusive.

“Resilience in tourism begins with clarity, which comes from hard-hitting data,” said Adam Sacks, President of Tourism Economics, an Oxford Economics company. “This white paper provides a data-driven roadmap for navigating uncertainty, enabling destinations to make informed choices and invest with confidence.”

Among its findings, the report projects a significant increase in international arrivals, rising from 1.5 billion today to 2 billion by 2030, driven in part by changing traveler preferences, with a marked emphasis on experiential value over cost. Tourists are increasingly seeking immersive, culturally authentic experiences, contributing to longer stays and higher per-trip spending.

To accommodate this demand, destinations that proactively include strategies such as adopting open visa regimes, traveler-centric policies, and forward-looking infrastructure are projected to be best positioned to capture a forecasted 40% increase in global travel demand by 2030.

This joint initiative reflects TOURISE’s ongoing commitment to fostering a tourism sector that is resilient, data-informed, and prepared to meet the challenges of a rapidly changing world.

Download the full white paper at TOURISE.com.

About TOURISE

TOURISE is the world’s premier platform shaping a new horizon for global tourism.

Under the umbrella of the Saudi Ministry of Tourism, powered by the Saudi Tourism Authority, the inaugural TOURISE Summit will take place November 11–13, 2025, in Riyadh, Saudi Arabia.

The event will convene visionaries from government, business, investment, tourism, and technology to drive transformative deals and deliver high-impact initiatives that redefine the future of the global tourism industry.

TOURISE ensures worldwide participation while offering access to decision-makers shaping the industry’s evolution. Following the Summit, TOURISE will continue as a year-round platform where bold ideas turn into real-world solutions.

This is where the next 50 years of tourism are shaped. Together, we are unstoppable.

For more information visit www.tourise.com.

About Oxford Economics

Oxford Economics is the world’s foremost independent economic advisory firm. Covering over 200 countries, 100 industrial sectors and 8,000 cities and regions, we provide insights and solutions that empower clients to make informed decisions faster in an increasingly complex and uncertain world.

For more information, visit https://www.oxfordeconomics.com/us/

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110254503/en/

Contacts

For media inquiries, please contact: press@oxfordeconomics.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye